Omar Baez

Sep 9, 2024 | cellandgene.com | Junwei Sun |Lucia Fernandez |Lucia Fernández |Omar Baez |Matthew Ercolino

Patient immune cells and varied raw materials introduce inherent biological variability into CAR-T therapy manufacturing, making it a constant balancing act of adjusting processes and technology to minimize batch-to-batch variability.

Aug 15, 2024 | outsourcedpharma.com | Omar Baez |Louis Garguilo

By Omar Baez, Comprehensive Cell Solutions The complex nature of cell therapy manufacturing necessitates a meticulous approach to development, production, and tech transfer. Achieving consistent product quality while adhering to stringent regulatory guidelines presents significant challenges. Traditional tech transfer methods often prove inadequate for the bespoke nature of these therapies, demanding a more tailored and collaborative approach.